Octreotide

( DrugBank: Octreotide / KEGG DRUG: Octreotide )

7 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
67	多発性嚢胞腎	7
75	クッシング病	1
84	サルコイドーシス	2
85	特発性間質性肺炎	1

告示番号	疾患名（ページ内リンク）	臨床試験数
89	リンパ脈管筋腫症	1
193	プラダー・ウィリ症候群	2
227	オスラー病	7

67. 多発性嚢胞腎

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

trials per page:

Showing 1 to 7 of 7 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03541447 (ClinicalTrials.gov)	December 12, 2018	17/5/2018	Tolvaptan-Octreotide LAR Combination in ADPKD	A Pilot, Phase II Study With a Prospective, Randomized, Cross-Over, Placebo-Controlled, Double-Blind ...	Autosomal Dominant Polycystic Kidney Disease	Drug: Tolvaptan;Drug: Octreotide LAR;Other: Placebo	Mario Negri Institute for Pharmacological Research	Otsuka Pharmaceutical Italy S.r.l.	Completed	18 Years	N/A	All	20	Phase 2	Italy
2	EUCTR2017-004701-40-IT (EUCTR)	06/08/2018	26/09/2019	STUDY TO ASSESS THE SHORT-TERM EFFECT OF THE ADMINISTRATION OF TOLVAPTAN AND OCTREOTIDELAR COMPARED ...	A PILOT, PHASE II STUDY WITH A PROSPECTIVE, RANDOMIZED, CROSS-OVER, PLACEBO-CONTROLLED, DOUBLE-BLIND ...	Autosomal Dominant Policiytic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 100 ...	Trade Name: JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFO ...	IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Italy
3	NCT01377246 (ClinicalTrials.gov)	May 2011	20/6/2011	Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Re ...	A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF ...	Autosomal Dominant Polycystic Kidney Disease	Drug: Octreotide-LAR;Other: Saline solution.	Mario Negri Institute for Pharmacological Research	NULL	Completed	18 Years	75 Years	All	100	Phase 3	Italy
4	EUCTR2011-000138-12-IT (EUCTR)	04/04/2011	28/12/2011	A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of ...	A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of ...	Autosomal Dominant Polycystic Kidney Disease MedDRA version: 14.1;Level: LLT;Classification code 100 ...	Trade Name: SANDOSTATINA LAR INN or Proposed INN: Octreotide	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	80	Phase 3	Italy
5	EUCTR2009-012376-27-IT (EUCTR)	16/11/2009	30/11/2009	EFFECTS OF LONG-ACTING SOMATOSTATIN ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYC ...	EFFECTS OF LONG-ACTING SOMATOSTATIN ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYC ...	Polycystic Kidney MedDRA version: 12.1;Level: LLT;Classification code 10036046;Term: Polycystic kidn ...	Trade Name: SANDOSTATINA LAR INN or Proposed INN: Octreotide	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	80	Phase 3	Italy
6	NCT00426153 (ClinicalTrials.gov)	January 2007	22/1/2007	Octreotide in Severe Polycystic Liver Disease	Pilot Study Of Long-Acting Octreotide(OctreotideLAR® Depot) In The Treatment Of Patients With Severe ...	Polycystic Kidney, Autosomal Dominant;Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Kidney, P ...	Drug: Octreotide;Drug: Placebo	Mayo Clinic	Novartis;National Center for Research Resources (NCRR)	Completed	18 Years	80 Years	All	42	Phase 2/Phase 3	United States
7	EUCTR2005-005552-41-IT (EUCTR)	20/02/2006	06/03/2007	Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant p ...	Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant p ...	Autosomal Dominant Polycystic Kidney Disease ADPKD MedDRA version: 6.1;Level: SOC;Classification cod ...	Trade Name: Sandostatina Lar IM Fl 20mg +2F Product Name: octreotide INN or Proposed INN: Octreotide	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	66	Phase 3	Italy

First Previous1Next Last

75. クッシング病

臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-003264-77-NL (EUCTR)	31/10/2011	07/09/2011	A study with ketoconazole and octreotide combination therapy for treatment of Cushing’s disease.	A prospective trial with ketoconazole and octreotidecombination therapy for treatment of Cushing’s d ...	Cushing's disease (which is caused by an ACTH producing pituitary adenoma) MedDRA version: 14.0;Leve ...	Trade Name: Octreotide Product Name: Octreotide Product Code: RVG 18236 Trade Name: Ketoconazole Product ...	Erasmus MC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands

First Previous1Next Last

84. サルコイドーシス

臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-002160-14-NL (EUCTR)	22/11/2016	25/10/2016	Octreotide PET/CT scan for the imaging of disease activity in neurologic and cardiac sarcoidosis.	68Ga-DOTA-NOC PET/CT for the imaging of disease activity in neurologic and cardiac sarcoidosis. - SC ...	Sarcoidosis.;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: Gallium-68-DOTA-N-Octreotide Product Code: Ga-68-DOTA-NOC INN or Proposed INN: Ga-68-DOT ...	St. Antonius Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Netherlands
2	EUCTR2013-005376-17-NL (EUCTR)	20/06/2014	27/02/2014	Sandostatin therapy in sarcoidosis	Sandostatin therapy in sarcoidosis - SST in SA	Sarcoidosis MedDRA version: 16.1;Level: HLGT;Classification code 10003816;Term: Autoimmune disorders ...	Trade Name: Sandostatin LAR INN or Proposed INN: OCTREOTIDE Other descriptive name: octreotideLAR / Sa ...	Erasmus Medical Center	NULL	Not Recruiting			Female: yes Male: yes			Netherlands

First Previous1Next Last

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00463983 (ClinicalTrials.gov)	October 2006	18/4/2007	Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide	Phase 2 Study of Long Acting Octreotide in Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: octreotide	Institut National de la Santé Et de la Recherche Médicale, France	NULL	Completed	40 Years	N/A	Both	25	Phase 1/Phase 2	France

First Previous1Next Last

89. リンパ脈管筋腫症

臨床試験数 : 38 / 薬物数 : 38 - (DrugBank : 15) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 118

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00005906 (ClinicalTrials.gov)	June 2000	9/6/2000	Treatment With Octreotide in Patients With Lymphangioleiomyomatosis	Treatment With Octreotide in Patients With Lymphangioleiomyomatosis	Lymphangioleiomyomatosis;Lymphangiomyomas;Pleural Effusions;Ascites	Drug: Octreotide	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	18 Years	65 Years	Female	4	Phase 2	United States

First Previous1Next Last

193. プラダー・ウィリ症候群

臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00399893 (ClinicalTrials.gov)	December 2006	14/11/2006	Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)	Investigation of the Developmental, Nutritional and Hormonal Regulation of Ghrelin in Children and Y ...	Prader-Willi Syndrome	Drug: Octreotide;Drug: Placebo	Duke University	National Institutes of Health (NIH);National Center for Research Resources (NCRR);Novartis	Terminated	5 Years	21 Years	All	5	N/A	United States
2	NCT01613495 (ClinicalTrials.gov)	August 2005	13/4/2011	Ghrelin Suppression by Octreotide in Prader-Willi	Ghrelin Suppression by Sandostatin LAR® Depot (OctreotideAcetate for Injectable Suspension) in Patie ...	Prader Willis Syndrome	Drug: Placebo;Drug: Octreotide	Oregon Health and Science University	NULL	Active, not recruiting	18 Years	N/A	Male	2	N/A	NULL

First Previous1Next Last

227. オスラー病

臨床試験数 : 56 / 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

trials per page:

Showing 1 to 7 of 7 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-004179-11-IT (EUCTR)	03/09/2021	17/08/2021	Effectiveness of somatostatin analogues for GI bleeding in patients with hereditaryhemorrhagic telan ...	Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagictelangiectasia and sy ...	Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease(in specific pat ...	Product Name: octreotidea azione pronta 0,1 mg Product Code: [OCTREOTIDEACETATO] INN or Proposed INN: ...	RADBOUD UNIVERSITY MEDICAL CENTER	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	38	Phase 3	France;Denmark;Netherlands;Germany;United Kingdom;Italy
2	EUCTR2018-004179-11-FR (EUCTR)	20/01/2021	26/11/2020	The effectiveness of Octreotidein hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber di ...	Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and s ...	Hereditary hemorrhagic telangiectasia (HHT);Therapeutic area: Diseases [C] - Congenital, Hereditary, ...	Trade Name: Octreotide INN or Proposed INN: OCTREOTIDE	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	38	Phase 3	France;Germany;Netherlands
3	EUCTR2018-004179-11-DE (EUCTR)	12/08/2020	12/03/2020	The effectiveness of Octreotidein hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber dis ...	Effectiveness of Somatostatin Analogues in Patients with hereditaryhemorrhagic telangiectasia and sy ...	Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease (in specific pa ...	Other descriptive name: OCTREOTIDE ACETATE	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	38	Phase 3	France;Netherlands;Germany;United Kingdom;Italy
4	EUCTR2018-004179-11-NL (EUCTR)	03/06/2019	14/05/2019	The effectiveness of Octreotidein hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber di ...	Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and s ...	Hereditary hemorrhagic telangiectasia (HHT);Therapeutic area: Diseases [C] - Congenital, Hereditary, ...	Trade Name: Octreotide INN or Proposed INN: OCTREOTIDE	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	38	Phase 3	Netherlands
5	NCT02874326 (ClinicalTrials.gov)	October 2016	17/8/2016	Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber	An Uncontrolled, Pilot-study Assessing the Efficacy of OctreotideLong-acting Release to Decrease Tra ...	Hereditary Hemorrhagic Telangiectasia;Gastrointestinal Hemorrhage;Anemia	Drug: Octreotide LAR	Radboud University	St. Antonius Hospital	Unknown status	18 Years	N/A	All	15	Phase 2	Netherlands
6	EUCTR2016-001340-19-NL (EUCTR)	21/07/2016	11/07/2016	The effectiveness of the drug octreotideLAR to anemia in patients with gastrointestinal bleeding due ...	An uncontrolled, pilot-study assessing the efficacy of octreotideLAR to decrease transfusion require ...	Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia ...	Trade Name: Sandostatin LAR 20 mg Product Name: Sandostatin LAR Product Code: RVG 18236	Radboud University Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Netherlands
7	NCT00004327 (ClinicalTrials.gov)	January 1995	18/10/1999	Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrha ...		Hereditary Hemorrhagic Telangiectasia;Ectasia	Drug: octreotide	National Center for Research Resources (NCRR)	Yale University	Completed	N/A	N/A	Both	8	Phase 2	NULL

First Previous1Next Last